CureVac (NASDAQ:CVAC – Free Report) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of CureVac in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($0.54) per share for the year, up from their prior estimate of ($0.60). The consensus estimate for CureVac’s current full-year earnings is $0.72 per share.
CureVac Trading Down 2.8 %
NASDAQ:CVAC opened at $3.85 on Friday. The firm’s fifty day moving average is $3.31 and its 200-day moving average is $3.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. CureVac has a 52 week low of $2.21 and a 52 week high of $5.28. The firm has a market cap of $861.94 million, a P/E ratio of 7.00 and a beta of 2.50.
Institutional Investors Weigh In On CureVac
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
- Five stocks we like better than CureVac
- What is the Dogs of the Dow Strategy? Overview and Examples
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- 3 Stocks to Consider Buying in October
- 3 Buy-and-Hold Stocks for Long-Term Growth
- What is a Dividend King?
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
